GW Pharmaceuticals Plc
(NASDAQ : GWPH)

( )
GWPH PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
VRXValeant Pharmaceuticals International, Inc. 0.67%28.5514.1%$167.99m
AMRNAmarin Corp. Plc 0.97%19.851.7%$164.08m
AXSMAxsome Therapeutics, Inc. 0.00%86.971.9%$91.78m
BHCBausch Health Cos., Inc. 0.67%28.550.0%$87.86m
GWPHGW Pharmaceuticals Plc 0.03%111.656.2%$72.20m
JAZZJazz Pharmaceuticals Plc -0.95%144.352.3%$67.26m
PRGOPerrigo Co. Plc 1.28%59.406.8%$66.67m
ICPTIntercept Pharmaceuticals, Inc. -3.85%92.9316.9%$61.67m
HZNPHorizon Therapeutics Plc -0.08%36.036.6%$58.95m
SAVACassava Sciences, Inc. 4.76%7.490.0%$58.91m
SAGESAGE Therapeutics, Inc. -0.48%67.008.6%$57.35m
MNKMallinckrodt Plc 2.88%5.0020.9%$43.59m
ICLRICON plc -1.79%171.824.2%$40.74m
CTLTCatalent, Inc. 0.70%62.012.4%$40.26m
UTHRUnited Therapeutics Corp. 0.81%90.0514.3%$35.97m

Company Profile

GW Pharmaceuticals Plc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It offers its lead cannabinoid product, Epidiolex oral solution CV, a pharmaceutical formulation of cannabidiol (CBD) focusing on the treatment of seizures associated with tuberous sclerosis complex. The company was founded by Geoffrey William Guy and Brian Whittle in 1998 and is headquartered in Cambridge, the United Kingdom.